RVNC - Revance Therapeutics submits sBLA for Daxxify for cervical dystonia
- Revance Therapeutics ( NASDAQ: RVNC ) has submitted a supplemental Biologics License Application (sBLA) to the US FDA for Daxxify (daxibotulinumtoxinA-lanm) to gain an indication for cervical dystonia.
- The ailment is a chronic condition in which the neck muscles contract involuntarily, causing abnormal movements and awkward posture of the head and neck.
- The company said the US market for muscle movement disorders is ~$1B.
- Daxxify was approved earlier this year for the reduction of frown lines.
- Seeking Alpha's Quant Rating views Revance ( RVNC ) as a buy with high marks for momentum and growth .
For further details see:
Revance Therapeutics submits sBLA for Daxxify for cervical dystonia